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Cardiovascular disease (CVD) is the principal cause of
mortality in patients with chronic renal disease undergoing
hemodialysis. In addition to the CVD risk factors, a new hy-
pothesis has recently been aroused related to “new” factors
involved in the development of atherosclerosis in the uremic
patient; worthwhile mentioning are the homocysteine, inflam-
mation, and oxidative stress, among others. The potential utility
of the folic acid in the hyperhomocysteinemia control is well
known, although its mechanism of action, either as antioxidant
or anti-inflammatory, has not been established.
Our results confirm that the patients undergoing dialysis
demonstrate hyperhomocysteinemia, an increased inflamma-
tory status, and an increase of the lipid peroxidation markers.
The administration of IV folinic acid induces a reduction of ho-
mocysteine levels subordinate to the inflammatory status of the
patient. Additionally, although no inflammatory effects were
shown, the results provide evidence for the antioxidant effect
of IV folinic acid administration by reducing the lipid peroxi-
dation marker levels.
The statistic analysis demonstrates no correlation among the
3 markers, in spite of its higher levels in these particular pa-
tients. Homocysteine does not independently predict mortal-
ity in patients taking oral folic acid. Nevertheless, the PCR
(an inflammation marker) and the antibody antioxidative-LDL
(a lipidic peroxidation marker) show a good prediction of mor-
tality at the 24-month follow-up analysis.
The knowledge of these “new” CV risk factors, as well as
the factors that influence them, could be useful to prevent the
development of atherosclerosis in patients with chronic renal
disease.
Cardiovascular disease (CVD) is very common in kid-
ney patients, and is, in fact, the main cause of morbid-
ity and mortality in this population. Classic risk factors
(diabetes mellitus, smoking, dyslipidemia, high blood
pressure, sedentary lifestyle, and obesity) and cardio-
vascular risk factors related to uremia (hypervolemia,
anemia, hyperdynamic status induced by vascular access,
and secondary hyperparathyroidism) do not fully explain
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the high incidence of cardiovascular disease in these pa-
tients [1]. More data continue to arise which suggest that
other factors, known as “emergent,” “new,” or “nonclas-
sic,” must play a role [2]. Among these “new” cardiovas-
cular risk factors, homocysteine, inflammation markers
(C-reactive protein), and oxidative stress should be
emphasized.
“NEW” CARDIOVACULAR RISK FACTORS:
HOMOCYSTEINE, LIPID PEROXIDATION,
AND INFLAMMATION
Homocysteine is an amino acid derived from the con-
version of methionine into cysteine. The participation of
different vitamins is required for its metabolization. In
the trans-sulfuration route, homocysteine is transformed
into cysteine by 2 vitamin B6-dependent reactions. In the
remethylation route, homocysteine is methylated to form
methionine by 2 independent metabolic routes in which
the enzymes 5-methyltetrahydrofolate-homocysteine
S-methyltransferase (methionine synthase) and betaine:
homocysteine methyltransferase participate. Methionine
synthase requires the 5-methyltetrahydrofolic acid as co-
substrate and methylcobalamine as a cofactor.
Kidney patients present hyperhomocysteinemia as a
result of delayed elimination and altered metabolization
(i.e., remethylation). Thus, while the prevalence of hy-
perhomocysteinemia (plasma homocysteine levels >15
lmol/L) in the general population is approximately 5%,
in dialysis patients it reaches 80% to 90% [3, 4].
Several studies have analyzed the role of homocysteine
in atherosclerosis development, and it has recently been
suggested that moderate hyperhomocysteine may dam-
age endothelial cell function in various ways. A possible
cellular and molecular mechanism of endothelial lesion is
oxidative damage [5]. Hyperhomocysteinemia may favor
oxidative damage, since homocysteine oxidizes rapidly
when released into plasma, and, as a consequence of the
auto-oxidation, a great amount of oxygen-free radicals—
radical superoxide and hydrogen peroxide—are gener-
ated [6]. These oxygen-free radicals are believed to cause
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the endothelial cytotoxicity of homocysteine, partly be-
cause they favor lipid peroxidation, an effect that occurs
on the surface of endothelial cells and plasma lipoprotein
particles [7].
Lipid peroxidation and particularly, oxidative modifi-
cations of LDL, are important factors in atherosclerosis
development and, indeed, sufficient data exist indicating
that LDL oxidation is present in human atherosclerotic
lesions [8]. Malondialdehyde (MDA) is the simplest usual
marker among those used to assess lipid peroxidation in
vivo, but it has the disadvantage of being rather nonspe-
cific [9]. Oxidated anti-LDL antibody titer is a widely
used specific lipid peroxidation marker to identify and
quantify oxidative stress.
The uremic patient presents chronic inflammatory sta-
tus resulting from various factors: raised cytokine pro-
duction and reduced renal clearance, AGE accumulation,
presence of chronic heart failure, arteriosclerosis, per
se, diverse inflammatory diseases, nondetected persistent
infections, and dialysis-related factors, such as bioincom-
patibility of dialysis membranes, or exposure to endo-
toxins and other substances of the dialyzer that induce
cytokine release [10]. C-reactive protein (CRP) is the first
acute-phase reactant described, and is one of the most
important of those presenting an increase during the in-
flammatory process.
The relationship between hyperhomocysteinemia and
inflammation has long been the object of research [11].
Several studies on investigating the molecular conse-
quences of hyperhomocysteine on the vessel wall found
nuclear factor kappa B (NF-jB) activation through an
oxidative mechanism. Low free radical concentrations
(H2O2-hydrogen peroxide) activate enzymes that phos-
phorylate the inhibitory protein, and the active form of
NF-jB remains, which stimulates the target genes. NF-
jB is a transcription factor necessary for remodeling cell
proinflammatory response [12]. Control of cytokine re-
lease and adhesion molecules (VCAM-1) is known to
be partially mediated by NF-jB activation [13]. Other
inflammation markers, such as TNF-a, may potentiate
the proinflammatory effect of hyperhomocysteinemia
and stimulate adhesion molecule (VCAM-1, ICAM-1, e-
selectin) activation [14] (Fig. 1). Adhesion molecules and
proinflammatory cytokines constitute important parts in
the binding of inflammatory mononuclear cells to the ves-
sel wall. These markers have been detected in atheroscle-
rosis, unstable angina, or acute myocardial infarction, and
correlate with plasma CRP concentrations [15].
ROLE OF THE FOLIC ACID AND RELATION
WITH THE “NEW” CARDIOVASCULAR RISK
FACTORS
Different treatments to control hyperhomocysteine-
mia (betaine, serine, and N-acetylcysteine [16]) have been
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Fig. 1. Relationship between homocysteine, inflammation markers,
and lipid peroxidation. Abbreviations are: RSH, thiol-bound sulfhydril
group; RSSR, mixed disulfide group of homocysteine and thiolactone
homocysteine which appears after homocysteine auto-oxidation; RL,
oxygen free radicals; GPx, peroxidase glutathione enzyme; ON, nitric
oxide.
assayed; however, many studies have shown vitamin sup-
plements to be the most effective. Antioxidants have
proved to neutralize hyperhomocysteinemia-induced en-
dothelial dysfunction [17]. In a previous study, we ana-
lyzed for the first time the relationship between oxidative
stress and homocysteine in hemodialysis patients and the
role of folic acid in these “new” CVD risk factors. We
showed that hemodialysis patients presented moderate-
severe hyperhomocysteinemia (mean homocysteine
levels pretreatment 38 lmol/L) that, following the intra-
venous administration of 10 mg of folinic acid 3 times a
week, dropped by 44% (mean homocysteine levels post-
treatment 21 lmol/L), but without reaching normal levels.
This same study showed that, further to the reduction in
homocysteine levels, a statistically significant reduction in
lipid peroxidation was achieved: a 40% decrease in MDA
concentration, and 13% in oxidated anti-LDL antibody
titer [18] (Fig. 2). These results suggest that folinic acid ex-
erts an indirect antioxidant effect by reducing the prooxi-
dant action of homocysteine and, consequently, lowering
oxidative stress.
Despite the high prevalence of inflammation in pa-
tients with chronic kidney failure, recommendations as to
whether this should be the object of treatment, and how
this should be carried out, remain to be established. Folic
acid is known to reduce hyperhomocysteine-induced ad-
hesion molecule expression by 50% [14]. We analyzed the
effect of inflammatory status on homocysteine response
to vitamin supplements in 15 stable patients on hemodial-
ysis who had received 75 mg of IV folinic acid at the end
of each dialysis session. Serum CRP concentrations did
not change following folinic acid administration (Table 1).
No correlation was found between plasma homocysteine
concentration and serum CRP levels; however, the study
shows that a decreased percentage of homocysteine levels
with IV folinic acid supplements depends on the serum
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Fig. 2. Effect of IV folinic acid on plasma homocysteine concentration
and lipid peroxidation marker (malondialdehyde). Abbreviations are:
MDA, malondialdehide (lmol/L); Hcy-homocysteine (lmol/L); Basal-
HD, at start of the study; Folinic-HD,10 mg of folinic acid intravenously
3 days per week. Statistic analyses were performed using the nonpara-
metric Wilcoxon test for paired data. P < 0.05 between control and
basal HD. P < 0.05 between basal and folinic HD.
Table 1. Serum folic acid concentrations, serum C-reactive protein
(CRP), and plasma homocysteine (Hcy) concentrations in the 3 study
periods
Folinic acid Folinic acid
25 mg/wk Washout 75 mg/wk
Serum folic ng/mL 8.49 ± 2.29 5.52 ± 4.54a 15.95 ± 4.07b
CRP mg/dL 10.10 ± 7.59 12.26 ± 9.80a 13.57 ± 9.8
Hcy lmol/L 19.34 ± 4.18 22.92 ± 6.9a 18.00 ± 4.80b
% Hcy +16.91 −20.43
Abbreviations are: CRP, C-reactive protein; Hcy, homocysteine; % Hcy,
homocysteine variation. Pearson’s correlation coefficient was used to analyze
the quantitative variables.
aP < 0.05 vs. folinic acid 25 mg/week.
bP < 0.05 vs. wash-out.
folic acid concentration (r = −0.60; P = 0.003) and the
patient’s basal CRP concentration (r = −0.66; P = 0.007)
(Fig. 3). When adjusted in a linear regression analysis by
serum folic acid values of the washout period by each in-
crease in 1 mg/dL of CRP concentration, the decreased
percentage of homocysteine dropped by 1.29%. Thus,
we can state that patients with lower inflammatory sta-
tus are those who present better response to folinic acid
treatment [abstract; Bonal J, J Am Soc Nephrol 13:212A,
2002].
RELATION BETWEEN THE “NEW”
CARDIOVASCULAR RISK FACTORS AND
MORTALITY
When these 3 “new” CV risk factors were analyzed
together, the relationship between homocysteine, inflam-
mation, oxidative stress, and cardiovascular disease in the
dialyzed population was found to be complex and, on oc-
casion, the studies yielded conflicting results.
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Fig. 3. Relationship between inflammatory state (C-reactive protein)
and homocysteine response (% homocysteine concentration decrease)
to treatment with folinic acid (75 mg/wk).
The relationship between homocysteine and
atherosclerosis in the dialysis population has been
reflected in several works. In 1997, Bostom et al
[19] presented a prospective study of 73 subjects on
dialysis receiving vitamin supplements in whom they
demonstrated a relationship between homocysteine
concentration and cardiovascular disease. These data
were later confirmed by other studies [20, 21]. In any
event, other works exist in which no relationship between
homocysteine concentrations and cardiovascular disease
[22], or even an inverse correlation [23], was found.
The role of CRP in cardiovascular disease develop-
ment in dialyzed patients is controversial, and CRP has
frequently been considered an epiphenomenon, rather
than a pathogenic mechanism [24]. However, CRP has
been isolated in the inflammatory lesion of atheroscle-
rotic vessels and myocardial infarcted zones, which sug-
gests that CRP and activation of the complement (classic
pathway) play a pathogenic role [25]. Several published
studies show that CRP is an independent predictor of
mortality in hemodialysis patients regardless of other fac-
tors, even after a follow-up period of 4 years [26].
On the other hand, the role of oxidated anti-LDL anti-
body titer and its relationship with atherosclerosis in kid-
ney failure patients has been less studied. Stenvinkel et al
[27] demonstrated that patients with carotid plaque have
a statistically significant high oxidated anti-LDL antibody
titer compared with those without atheromatous plaque.
By contrast, Shoji et al [28] reported that, in hemodialysis
patients, a higher oxidated anti-LDL antibody titer is a
low mortality risk factor for cardiovascular disease, and
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Table 2. Analytic parameters and age according to vital status at the
end of follow-up: Unadjusted mortality-related risk factors
CI 95%
Death Survival OR lower-higher P value
Age years 74 ± 7 63 ± 16 1.05 1.01–1.09 <0.01
CRP mg/L 9.72 4.86 3.28 1.14–9.44 0.03
(0.39–88) (0.35–87)
Hcy lmol/L 26.36 ± 6.99 25.60 ± 8.26 1.01 0.97–1.06 0.51
IgG 191 ± 85 147 ± 68 1.01 1.002–1.010 <0.01
oxLDL-Ab
(ODx1000)
Abbreviations are: CRP, C-reactive protein; Hcy, homocysteine; IgG
oxLDL-Ab, plasma copper oxidized anti-LDL antibodies. Risk of death during
follow-up was analyzed by a Cox proportional risk model.
they found no relationship with noncardiovascular dis-
ease mortality. The reasons for such discrepancies among
studies are unknown; however, most observations in the
general population suggest that the oxidated anti-LDL
antibody titer is raised in cases of advanced atheroscle-
rosis [29–31].
We studied these “new” cardiovascular risk factors
in 94 patients on hemodialysis treated with oral vita-
min supplements (folic acid and vitamin B complex)
and followed-up for 24 months. The patients presented
chronic inflammatory status, high oxidated anti-LDL an-
tibody titer, and moderate hyperhomocysteinemia. Al-
though a relationship between the 3 CVD risk factors was
theoretically possible, we found no correlation between
these “new” CVD risk factors studied. Cox analysis re-
vealed that homocysteine is not a mortality risk factor in
this study population supplemented with vitamins. Statis-
tic analysis confirmed that inflammation (CRP) and ox-
idative stress, together with age, are the main risk factors
for mortality in this population (Table 2) [32]. The reduc-
tion in homocysteine levels achieved after vitamin sup-
plementation may lead to patients presenting very similar
homocysteine concentrations, and to losing importance
as a cardiovascular risk factor and predictor of mortality.
These results, together with the reduction in lipid peroxi-
dation achieved after folic acid administration, underline
the importance of vitamin administration in kidney pa-
tients to avoid deficits, and neutralize the elevated oxida-
tive stress frequently presented.
CONCLUSION
The rapid development of atherosclerosis in uremia is
a complex, multifactorial process; however, it should be
emphasized that the role of inflammation and oxidative
stress in its etiopathogeny is increasingly clear. Knowl-
edge of these “new” risk factors may help to prevent the
development of atherosclerosis in these patients.
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